Browsing: receives

INDIANAPOLIS, Aug. 24, 2026 /PRNewswire/ — Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has cleared the Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test, providing clinicians across primary and specialty care with a single blood-based option to aid in identifying amyloid pathology associated with Alzheimer’s disease in individuals 55…

UCLA Health’s Dr. Arpana Church has received a $4 million federal grant to test whether a specific probiotic blend can influence the communication network linking the gut, its microbiome and the brain in adults with obesity, with the goal of understanding how these changes may influence food cravings and eating behaviors

— Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan —

Rare disease specialist Ultragenyx’s gene therapy Genglycos has received accelerated approval from the FDA for treatment of glycogen storage disease type Ia (GSDIa), a rare metabolic condition

MISSISSAUGA, ON, Aug. 18, 2026 /CNW/ — GSK is pleased to announce that Nucala (mepolizumab) has received a positive reimbursement recommendation with conditions from Canada’s Drug Agency (CDA-AMC). The agency recommends that Nucala be reimbursed as an add-on maintenance treatment in adult patients with COPD characterized by raised blood eosinophils, inadequately controlled by the combination of an inhaled corticosteroid…

Pila Pharma reports that it has received EMA approval to start a clinical trial to evaluate the safety and tolerability of increasing doses of XEN-D0501 versus placebo over 12 weeks of dosing in obese participants. We are encouraged that the start of clinical development in obesity at higher and potentially more clinically relevant doses now…

Carlsquare Equity Research has published a comment on today’s news regarding EMA approval for the start of a new clinical trial for XEN-D0501

Designation follows recent FDA clearance of the Company’s IND application for C-1101, an investigational, potentially disease-modifying non-opioid biologic

NEW YORK, Aug 18, 2026 – (ACN Newswire) – Broad Investment Securities LLC, a U.S. SEC-registered investment adviser, has issued an independent fundamental research report on Tokyo Lifestyle Co., Ltd. (Nasdaq: TKLF), examining the Japanese consumer-products distributor’s business model, financial trajectory, channel mix and international expansion

The five-year grant aims to address a critical gap in HIV care for people with active methamphetamine use disorder through an innovative, multidisciplinary approach to treatment